银屑病患者中依奇珠单抗与司库奇尤单抗真实世界治疗模式比较
本研究基于IBM MarketScan数据库的回顾性队列,纳入2016年3月至2018年5月使用依奇珠单抗或司库奇尤单抗的银屑病患者,采用逆概率加权和多变量模型比较治疗持续性、停药、换药及依从性。结果显示依奇珠单抗使用者持续率更高(54.8% vs 45.1%,P < .001)、停药率更低(37.8% vs 47.5%,P < .001),调整后非持续和停药风险更低,高依从性几率更高,换药风险相似。
要点
- 依奇珠单抗使用者持续率54.8%,高于司库奇尤单抗的45.1%(P < .001)。
- 依奇珠单抗停药率37.8%,低于司库奇尤单抗的47.5%(P < .001)。
- 调整后依奇珠单抗非持续风险HR 0.82(95%CI 0.71-0.95),停药风险HR 0.82(95%CI 0.70-0.96)。
核心结论
- 在真实临床实践中,依奇珠单抗使用者较司库奇尤单抗使用者显示更长的药物持续性、更低的停药率和停药风险、更高的依从可能性,换药风险相似。
研究设计与样本
- 回顾性队列研究,纳入2016年3月1日至2018年5月31日IBM MarketScan数据库中年龄≥18岁、接受依奇珠单抗或司库奇尤单抗治疗的银屑病患者。
- 使用逆概率治疗加权和多变量模型处理队列不平衡,估计非持续(60天缺口)、停药(≥90天缺口)、换药风险及依从性比值比。
- 监测645例依奇珠单抗使用者13.7个月,1152例司库奇尤单抗使用者16.3个月。
主要发现
- 依奇珠单抗使用者持续率54.8%,司库奇尤单抗使用者45.1%(P < .001)。
- 依奇珠单抗使用者停药率37.8%,司库奇尤单抗使用者47.5%(P < .001)。
- 多变量调整后,依奇珠单抗使用者非持续风险HR 0.82(95%CI 0.71-0.95),停药风险HR 0.82(95%CI 0.70-0.96)。
- 以药物持有率≥80%衡量的高依从性几率HR 1.31(95%CI 1.07-1.60)。
- 两组换药风险相似。
关键数值与推荐
- 非持续定义为60天治疗缺口,停药定义为≥90天缺口。
- 高依从性定义为药物持有率≥80%。
临床怎么用
- 在银屑病生物制剂选择中,可参考真实世界治疗持续性数据,依奇珠单抗可能具有更优的持续性和依从性。
局限性
- 缺乏疾病严重程度和临床结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Real-world data on treatment patterns associated with use of interleukin-17A inhibitors in psoriasis are lacking. OBJECTIVE: To compare treatment patterns between ixekizumab or secukinumab users in clinical practice. METHODS: A retrospective cohort study included patients with psoriasis aged ≥18 years treated with ixekizumab or secukinumab between March 1, 2016, and May 31, 2018 in IBM MarketScan (IBM Corp, Armonk, NY) databases. Inverse probability of treatment weighting and multivariable models were used to address cohort imbalances and estimate the risks of nonpersistence (60-day gap), discontinuation (≥90-day gap), switching, and the odds of adherence. RESULTS: The study monitored 645 ixekizumab users for 13.7 months and 1152 secukinumab users for 16.3 months. Ixekizumab users showed higher persistence rate (54.8% vs 45.1%, P < .001) and lower discontinuation rate (37.8% vs 47.5%, P < .001) than secukinumab. After multivariable adjustment, ixekizumab users had lower risks of nonpersistence (hazard ratio, 0.82; 95% confidence interval, 0.71-0.95) and discontinuation (hazard ratio, 0.82; 95% confidence interval, 0.70-0.96), and higher odds of high adherence to treatment measured by a medication possession ratio ≥80% (hazard ratio, 1.31; 95% confidence interval, 1.07-1.60). The risk of switching was similar between cohorts. LIMITATIONS: Disease severity and clinical outcomes were unavailable. CONCLUSION: Ixekizumab users demonstrated longer drug persistence, lower discontinuation rate and risk of discontinuation, higher likelihood of adherence, and similar risk of switching compared with secukinumab users in clinical practices.
引用
- Blauvelt A, Shi N, Burge R, et al. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab. J Am Acad Dermatol. 2019. PMID: 31712178. doi:10.1016/j.jaad.2019.11.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。